Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DILSHER S DHOOT

Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist

NPI
1508070566
CMS profile
1089026
Location
SANTA BARBARA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$408,770.50

345 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 5 of 7; records 201–250 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DILSHER S DHOOT

NPI 1508070566 · CMS profile ID 1089026

Allopathic & Osteopathic Physicians / Ophthalmology / Retina Specialist

SANTA BARBARA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 7; records 201–250 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508070566?year=2024&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DILSHER S DHOOT, NPI 1508070566, CMS profile ID 1089026. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508070566?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). DILSHER S DHOOT, NPI 1508070566, CMS profile ID 1089026. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508070566?year=2024&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
DILSHER S DHOOT, NPI 1508070566, CMS profile ID 1089026, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 7; records 201–250 of 345 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1508070566?year=2024&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

345 matching records · $408,770.50 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 345 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 345.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $54.0005/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037341 CMS
Regeneron Healthcare Solutions, Inc. $19.9005/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037343 CMS
Regeneron Healthcare Solutions, Inc. $12.8505/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037345 CMS
Regeneron Healthcare Solutions, Inc. $29.7505/09/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037347 CMS
Astellas Pharma US Inc $160.0005/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139341142 CMS
Ocular Therapeutix, Inc. $500.0005/08/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148198221 CMS
NEW WORLD MEDICAL,INC. $186.9205/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137397731 CMS
Regeneron Healthcare Solutions, Inc. $5,290.0005/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037317 CMS
Regeneron Healthcare Solutions, Inc. $7,935.0005/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037319 CMS
Astellas Pharma US Inc $27.7605/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139333110 CMS
BioCryst Pharmaceuticals, Inc. $24.0905/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117472690 CMS
Ocular Therapeutix, Inc. $500.0005/05/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148198217 CMS
Ocular Therapeutix, Inc. $500.0005/05/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148198267 CMS
Regeneron Pharmaceuticals, Inc. $33.4805/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114398249 CMS
Ocular Therapeutix, Inc. $1,500.0005/04/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148198247 CMS
Regeneron Healthcare Solutions, Inc. $124.7305/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037313 CMS
Regeneron Healthcare Solutions, Inc. $239.1505/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037315 CMS
Sandoz Inc. $73.0005/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089367256 CMS
Regeneron Healthcare Solutions, Inc. $30.6605/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037309 CMS
Regeneron Healthcare Solutions, Inc. $152.3005/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037311 CMS
Genentech USA, Inc. $397.8805/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133002038 CMS
Genentech USA, Inc. $6,720.0005/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133002042 CMS
Genentech USA, Inc. $209.8405/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133002046 CMS
Genentech USA, Inc. $81.5105/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133002050 CMS
Genentech USA, Inc. $743.6005/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133002054 CMS
Genentech USA, Inc. $146.0905/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133002058 CMS
Regeneron Healthcare Solutions, Inc. $99.2904/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037307 CMS
Regeneron Healthcare Solutions, Inc. $340.7504/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037297 CMS
Regeneron Healthcare Solutions, Inc. $395.6004/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037299 CMS
Regeneron Healthcare Solutions, Inc. $369.2904/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037301 CMS
Regeneron Healthcare Solutions, Inc. $398.9804/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037303 CMS
Regeneron Healthcare Solutions, Inc. $308.1204/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037305 CMS
Regeneron Healthcare Solutions, Inc. $10,580.0004/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037295 CMS
Ocular Therapeutix, Inc. $1,500.0004/24/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148198227 CMS
Regeneron Healthcare Solutions, Inc. $238.5204/24/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037293 CMS
Genentech USA, Inc. $33.1504/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133002034 CMS
Regeneron Healthcare Solutions, Inc. $54.1004/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037291 CMS
Regeneron Healthcare Solutions, Inc. $577.5004/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037287 CMS
Regeneron Healthcare Solutions, Inc. $253.5004/20/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037289 CMS
Regeneron Healthcare Solutions, Inc. $239.2804/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037283 CMS
Regeneron Healthcare Solutions, Inc. $0.0104/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037285 CMS
Regeneron Healthcare Solutions, Inc. $40.0004/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037273 CMS
Regeneron Healthcare Solutions, Inc. $9.9504/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037275 CMS
Regeneron Healthcare Solutions, Inc. $12.3104/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037277 CMS
Regeneron Healthcare Solutions, Inc. $15.3804/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037279 CMS
Regeneron Healthcare Solutions, Inc. $29.7504/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037281 CMS
Regeneron Healthcare Solutions, Inc. $59.9504/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037271 CMS
EyePoint Pharmaceuticals US, Inc. $3,700.0004/15/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089507278 CMS
Regeneron Healthcare Solutions, Inc. $35.6204/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114037269 CMS
Apellis Pharmaceuticals, Inc. $30.7004/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154020036 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $300,383.36 293
PY2020 $64,636.57 79
PY2021 $173,500.47 157
PY2022 $229,270.69 237
PY2023 $477,925.12 371
PY2024 $408,770.50 345
PY2025 $277,352.21 262

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $24,711.52 7
PY2025 Principal investigator $1,978,226.05 546
PY2024 Recipient $67,234.88 20
PY2024 Principal investigator $1,146,034.35 196
PY2023 Recipient $10,830.67 7
PY2023 Principal investigator $588,583.13 38
PY2022 Recipient $7,047.37 4
PY2022 Principal investigator $353,849.05 30
PY2021 Recipient $9,275.99 5
PY2021 Principal investigator $692,497.36 32
PY2020 Recipient $29,746.12 15
PY2020 Principal investigator $891,321.57 23
PY2019 Recipient $7,478.66 8
PY2019 Principal investigator $632,947.67 12

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

553 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ocular Therapeutix, Inc. $1,865.00 12/31/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231520
Principal investigator 1 Ocular Therapeutix, Inc. $27,693.00 12/24/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231491
Principal investigator 1 Ocular Therapeutix, Inc. $3,469.22 12/24/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231495
Principal investigator 1 Ocular Therapeutix, Inc. $5,650.00 12/24/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231500
Principal investigator 1 Ocular Therapeutix, Inc. $19,845.00 12/17/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231479
Principal investigator 1 Ocular Therapeutix, Inc. $2,700.00 12/15/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231549
Principal investigator 1 Apellis Pharmaceuticals, Inc. $167.86 12/12/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362872
Principal investigator 1 Apellis Pharmaceuticals, Inc. $686.00 12/12/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362874
Principal investigator 1 Genentech, Inc. $7,627.00 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211582761
Principal investigator 1 Genentech, Inc. $2,800.00 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211582766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274002
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274004
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274006
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274008
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274010
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274012
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274014
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274016
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274018
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274022
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274024
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274026
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274028
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274032
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274034
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274042
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274044
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274046
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274050
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274056
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274058
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274060
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274062
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274064
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274066
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274068
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274070
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274072
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274078
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274080
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274084
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,680.10 12/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184274092
Principal investigator 1 Ocular Therapeutix, Inc. $3,001.81 12/10/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231462
Principal investigator 1 Ocular Therapeutix, Inc. $5,951.54 12/10/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231465
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,302.85 12/03/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184268363
Principal investigator 1 Genentech, Inc. $1,713.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211582770
Principal investigator 1 Ocular Therapeutix, Inc. $3,580.00 12/01/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231449
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.70 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267701
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267703
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267705
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267707
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267731
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 12/01/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184267741
Principal investigator 1 SANOFI US SERVICES INC. $23,300.00 12/01/2025 Non-covered Recipient Entity
California Retina Consultants
Age-related macular degeneration No dispute reported 06/30/2026 1226100435
Principal investigator 1 SANOFI US SERVICES INC. $3,623.00 12/01/2025 Non-covered Recipient Entity
California Retina Consultants
Age-related macular degeneration No dispute reported 06/30/2026 1226100445
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265217
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265221
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265225
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265227
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265231
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265233
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265235
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265237
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $236.25 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.70 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $135.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265291
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 11/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184265293
Principal investigator 1 Ocular Therapeutix, Inc. $3,580.00 11/19/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231405
Principal investigator 1 Ocular Therapeutix, Inc. $121,098.00 11/19/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231410
Principal investigator 1 Ocular Therapeutix, Inc. $3,004.00 11/19/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231418
Principal investigator 1 Ocular Therapeutix, Inc. $4,477.37 11/14/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231397
Principal investigator 1 Genentech, Inc. $665.00 11/13/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211582753
Principal investigator 1 Ocular Therapeutix, Inc. $1,640.00 11/12/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231371
Principal investigator 1 Ocular Therapeutix, Inc. $1,635.00 11/12/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231375
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 11/12/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231378
Principal investigator 1 Ocular Therapeutix, Inc. $5,133.64 11/12/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231387
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362836
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362838
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362840
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362842
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362844
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362846
Principal investigator 1 Apellis Pharmaceuticals, Inc. $872.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362848
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362850
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362852
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362854
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362856
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362858
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362860
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362862
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362864
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362866
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362868
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 11/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362870
Principal investigator 1 Genentech, Inc. $485.00 11/06/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211582757
Principal investigator 1 ABBVIE INC. $899.10 11/03/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy (RGX-314 SRLTFU) No dispute reported 06/30/2026 1202520039
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,930.50 10/30/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184255705
Principal investigator 1 Ocular Therapeutix, Inc. $2,633.00 10/29/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231360
Principal investigator 1 Ocular Therapeutix, Inc. $16,440.00 10/29/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231362
Principal investigator 1 Genentech, Inc. $4,596.00 10/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211582741
Principal investigator 1 Genentech, Inc. $3,106.00 10/16/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211582745
Principal investigator 1 Genentech, Inc. $300.00 10/15/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211582736
Principal investigator 1 Ocular Therapeutix, Inc. $1,350.00 10/15/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231545
Principal investigator 1 Ocular Therapeutix, Inc. $200.00 10/13/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231527
Principal investigator 1 Ocular Therapeutix, Inc. $6,969.00 10/10/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231352
Principal investigator 1 Genentech, Inc. $1,132.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211582749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249222
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249224
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249226
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249228
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249230
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249232
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249234
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249236
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249238
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249240
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249242
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249244
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249246
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249248
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249250
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.70 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249252
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249254
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249256
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249258
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249260
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249262
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249264
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $162.00 10/09/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184249266
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 10/08/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231326
Principal investigator 1 Ocular Therapeutix, Inc. $845.00 10/08/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231333
Principal investigator 1 Apellis Pharmaceuticals, Inc. $192.50 10/02/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362834
Principal investigator 1 Ocular Therapeutix, Inc. $29,259.00 10/01/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231322
Principal investigator 1 Genentech, Inc. $18,197.00 09/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211582729
Principal investigator 1 Genentech, Inc. $13,552.00 09/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211582733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184240984
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184240986
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184240988
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.70 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184240990
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184240992
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184240994
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184240996
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184240998
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241000
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241002
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241004
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241006
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241008
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241010
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241012
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241014
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241016
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241018
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241020
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241022
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241024
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241026
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241028
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241030
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241032
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241034
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241036
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241042
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241044
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241046
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241050
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241054
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241056
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241058
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241060
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241062
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241064
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241066
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241068
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241070
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241072
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241074
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241076
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241078
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241080
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241084
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $56.70 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241088
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241090
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241092
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241094
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241096
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241098
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241104
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241106
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241108
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 09/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184241110
Principal investigator 1 Genentech, Inc. $485.00 09/18/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211582722
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239742
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239744
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239746
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239748
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239750
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239756
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239758
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239760
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239762
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239764
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 09/17/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184239770
Principal investigator 1 Apellis Pharmaceuticals, Inc. $15,600.00 09/12/2025 Non-covered Recipient Entity
California Retina Consultants
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio No dispute reported 06/30/2026 1250362732
Principal investigator 1 Apellis Pharmaceuticals, Inc. $5,000.00 09/12/2025 Non-covered Recipient Entity
California Retina Consultants
A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio No dispute reported 06/30/2026 1250362734
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 09/12/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231314
Recipient Regeneron Pharmaceuticals, Inc. $1,135.83 09/05/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184117041
Principal investigator 1 Apellis Pharmaceuticals, Inc. $20.00 09/03/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362742
Principal investigator 1 Apellis Pharmaceuticals, Inc. $120.00 09/03/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362744
Principal investigator 1 Ocular Therapeutix, Inc. $1,769.00 09/03/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231282
Principal investigator 1 Ocular Therapeutix, Inc. $2,483.80 09/03/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231286
Principal investigator 1 Ocular Therapeutix, Inc. $4,974.51 09/03/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231289
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 09/03/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231293
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 09/03/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231297
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.55 09/03/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8.61 09/03/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234899
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/03/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234903
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/03/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/03/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $209.25 09/03/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184234909
Principal investigator 1 Ocular Therapeutix, Inc. $2,836.00 08/29/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231268
Principal investigator 1 Ocular Therapeutix, Inc. $34,579.00 08/29/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231272
Principal investigator 1 Ocular Therapeutix, Inc. $3,862.00 08/29/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231275
Principal investigator 1 ABBVIE INC. $1,603.80 08/27/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202506035
Principal investigator 1 Apellis Pharmaceuticals, Inc. $150.00 08/20/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362740
Principal investigator 1 Ocular Therapeutix, Inc. $16,147.00 08/20/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231249
Principal investigator 1 Ocular Therapeutix, Inc. $23,069.00 08/20/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231253
Principal investigator 1 Genentech, Inc. $300.00 08/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211582725
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 08/13/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231223
Principal investigator 1 Ocular Therapeutix, Inc. $13,740.00 08/13/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231241
Principal investigator 1 Ocular Therapeutix, Inc. $1,026.00 08/06/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231219
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223850
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223852
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223962
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223964
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184223966
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224072
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224082
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224766
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 08/06/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184224768
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $720.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222182
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,680.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222184
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $504.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $882.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222188
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $474.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,205.00 07/30/2025 Non-covered Recipient Entity
RETINA GROUP INC
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184222192
Principal investigator 1 ABBVIE INC. $8,000.00 07/25/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy No dispute reported 06/30/2026 1202499772
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 07/25/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231203
Principal investigator 1 Apellis Pharmaceuticals, Inc. $872.00 07/23/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362736
Principal investigator 1 Apellis Pharmaceuticals, Inc. $872.00 07/23/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362738
Principal investigator 1 Ocular Therapeutix, Inc. $3,013.19 07/18/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231166
Principal investigator 1 Ocular Therapeutix, Inc. $7,548.92 07/18/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231175
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 07/18/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231191
Principal investigator 1 Apellis Pharmaceuticals, Inc. $4,830.00 07/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362746
Principal investigator 1 Apellis Pharmaceuticals, Inc. $872.00 07/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362748
Principal investigator 1 Apellis Pharmaceuticals, Inc. $872.00 07/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362750
Principal investigator 1 Apellis Pharmaceuticals, Inc. $872.00 07/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362752
Principal investigator 1 Apellis Pharmaceuticals, Inc. $872.00 07/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362754
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,053.00 07/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362756
Principal investigator 1 Ocular Therapeutix, Inc. $15,561.00 07/16/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231153
Principal investigator 1 Ocular Therapeutix, Inc. $3,055.32 07/16/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231158
Principal investigator 1 Ocular Therapeutix, Inc. $42,448.00 07/16/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231162
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216104
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216114
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 07/16/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216116
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216118
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216120
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216124
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 07/16/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184216128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.09 07/10/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213696
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.11 07/10/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213698
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12.18 07/10/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184213700
Principal investigator 1 Ocular Therapeutix, Inc. $1,889.00 07/09/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231146
Principal investigator 1 Genentech, Inc. $10,762.00 07/07/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211582718
Principal investigator 1 Ocular Therapeutix, Inc. $9,972.20 07/04/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231133
Principal investigator 1 Ocular Therapeutix, Inc. $15,601.00 07/04/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231137
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 07/02/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231115
Principal investigator 1 Ocular Therapeutix, Inc. $5,000.00 07/02/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231124
Recipient Ocular Therapeutix, Inc. $11,231.29 06/30/2025 Covered Recipient Physician Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250229232
Principal investigator 1 Apellis Pharmaceuticals, Inc. $40.00 06/25/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362796
Principal investigator 1 Apellis Pharmaceuticals, Inc. $13.35 06/25/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362798
Principal investigator 1 Genentech, Inc. $21,517.00 06/25/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211582661
Principal investigator 1 Genentech, Inc. $1,419.00 06/25/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211582670
Principal investigator 1 Genentech, Inc. $66,607.00 06/25/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211582673
Principal investigator 1 Genentech, Inc. $1,927.00 06/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211582654
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 06/20/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362812
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 06/20/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362814
Principal investigator 1 Genentech, Inc. $268.00 06/18/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211582657
Principal investigator 1 Genentech, Inc. $255.00 06/18/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211582666
Principal investigator 1 Ocular Therapeutix, Inc. $765.00 06/18/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231077
Recipient Regeneron Pharmaceuticals, Inc. $179.52 06/17/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184117039
Principal investigator 1 Ocular Therapeutix, Inc. $1,082.20 06/13/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231065
Principal investigator 1 Ocular Therapeutix, Inc. $3,106.00 06/13/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231069
Principal investigator 1 Genentech, Inc. $485.00 06/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211582650
Principal investigator 1 Apellis Pharmaceuticals, Inc. $686.00 06/11/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362800
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 06/11/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231061
Principal investigator 1 Ocular Therapeutix, Inc. $2,641.40 06/06/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy No dispute reported 06/30/2026 1250231052
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202025
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202029
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202427
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202431
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202433
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,314.60 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202435
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202713
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202715
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202717
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202719
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202721
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 06/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184202723
Principal investigator 1 Genentech, Inc. $485.00 05/28/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
STUDY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1211582678
Principal investigator 1 Ocular Therapeutix, Inc. $24,936.00 05/28/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231038
Principal investigator 1 Ocular Therapeutix, Inc. $2,483.80 05/28/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231048
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3.36 05/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.93 05/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18.55 05/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198691
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $124.32 05/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6.09 05/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.11 05/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10.50 05/26/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184198699
Principal investigator 1 Ocular Therapeutix, Inc. $1,044.25 05/21/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231033
Principal investigator 1 Apellis Pharmaceuticals, Inc. $4,830.00 05/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362816
Principal investigator 1 Apellis Pharmaceuticals, Inc. $4,830.00 05/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362818
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 05/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362820
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 05/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362822
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 05/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362824
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 05/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362826
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 05/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362828
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 05/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362830
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,053.00 05/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362832
Principal investigator 1 Ocular Therapeutix, Inc. $10,774.00 05/16/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231030
Principal investigator 1 ANI Pharmaceuticals, Inc. $13,454.39 05/15/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
New Day Study No dispute reported 06/30/2026 1248567463
Principal investigator 1 Apellis Pharmaceuticals, Inc. $40.00 05/09/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362802
Principal investigator 1 Apellis Pharmaceuticals, Inc. $150.64 05/09/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362804
Principal investigator 1 Ocular Therapeutix, Inc. $2,936.00 05/09/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231020
Principal investigator 1 Genentech, Inc. $470.00 05/08/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211582710
Principal investigator 1 Genentech, Inc. $170.00 05/08/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211582714
Recipient Regeneron Pharmaceuticals, Inc. $7,960.50 05/05/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184117037
Principal investigator 1 Ocular Therapeutix, Inc. $44,639.00 04/30/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231006
Principal investigator 1 Ocular Therapeutix, Inc. $2,052.00 04/30/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231009
Principal investigator 1 Ocular Therapeutix, Inc. $18,707.00 04/30/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231015
Principal investigator 1 ANI Pharmaceuticals, Inc. $31,070.00 04/24/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
New Day Study No dispute reported 06/30/2026 1248567385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185529
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185531
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185535
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185541
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185543
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185545
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185547
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185549
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185553
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185555
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185567
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185569
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 04/23/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184185573
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 04/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362806
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 04/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362808
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,053.00 04/16/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362810
Principal investigator 1 Ocular Therapeutix, Inc. $4,016.24 04/16/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230972
Principal investigator 1 Ocular Therapeutix, Inc. $1,953.05 04/16/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230984
Principal investigator 1 Ocular Therapeutix, Inc. $6,377.00 04/16/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230988
Principal investigator 1 Ocular Therapeutix, Inc. $1,790.00 04/16/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230994
Principal investigator 1 Genentech, Inc. $32,667.00 04/11/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211582704
Principal investigator 1 Ocular Therapeutix, Inc. $3,500.00 04/09/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230953
Principal investigator 1 Ocular Therapeutix, Inc. $7,000.00 04/09/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230957
Principal investigator 1 Ocular Therapeutix, Inc. $4,863.00 04/09/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230961
Principal investigator 1 Ocular Therapeutix, Inc. $250.00 04/09/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230965
Principal investigator 1 Genentech, Inc. $5,253.00 04/08/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211582696
Recipient F. Hoffmann-La Roche AG $579.38 03/31/2025 Covered Recipient Physician VA2 PhIII Yosemite No dispute reported 06/30/2026 1211535444
Principal investigator 1 Ocular Therapeutix, Inc. $25,515.00 03/21/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231095
Principal investigator 1 Apellis Pharmaceuticals, Inc. $4,830.00 03/14/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362766
Principal investigator 1 Apellis Pharmaceuticals, Inc. $4,830.00 03/14/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362768
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 03/14/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362770
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 03/14/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362772
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 03/14/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362774
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 03/14/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362776
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 03/14/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362778
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,053.00 03/14/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362780
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,053.00 03/14/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172780
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172782
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172788
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172790
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,436.10 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172792
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172794
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172796
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172800
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172952
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172954
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172956
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172958
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172960
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172964
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172966
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172968
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,225.85 03/12/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184172970
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/10/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184170680
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/10/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184170682
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/10/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184170684
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/10/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184170686
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/10/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184170688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/10/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184170690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/10/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184170692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/10/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184170694
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/10/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184170696
Principal investigator 1 Ocular Therapeutix, Inc. $23,131.00 03/07/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231088
Principal investigator 1 Ocular Therapeutix, Inc. $437.00 03/05/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250231085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156834
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,026.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156836
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156838
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156840
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156842
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156844
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 03/05/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184156846
Principal investigator 1 Ocular Therapeutix, Inc. $15,872.00 02/26/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230929
Principal investigator 1 ANI Pharmaceuticals, Inc. $2,350.00 02/19/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
New Day Study No dispute reported 06/30/2026 1248567457
Principal investigator 1 Apellis Pharmaceuticals, Inc. $4,830.00 02/19/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362758
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 02/19/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362760
Principal investigator 1 Ocular Therapeutix, Inc. $23,958.00 02/19/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230909
Principal investigator 1 Ocular Therapeutix, Inc. $3,580.00 02/19/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230913
Principal investigator 1 Apellis Pharmaceuticals, Inc. $686.00 02/07/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362764
Principal investigator 1 Ocular Therapeutix, Inc. $8,811.00 02/05/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230883
Principal investigator 1 Ocular Therapeutix, Inc. $3,500.00 02/05/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230898
Principal investigator 1 ANI Pharmaceuticals, Inc. $11,200.00 01/30/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
New Day Study No dispute reported 06/30/2026 1248567541
Principal investigator 1 Ocular Therapeutix, Inc. $1,921.00 01/29/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230936
Principal investigator 1 Ocular Therapeutix, Inc. $2,810.00 01/29/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230940
Principal investigator 1 Ocular Therapeutix, Inc. $6,211.00 01/29/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230945
Principal investigator 1 Genentech, Inc. $234.00 01/28/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS No dispute reported 06/30/2026 1211582681
Principal investigator 1 ANI Pharmaceuticals, Inc. $3,710.75 01/24/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
New Day Study No dispute reported 06/30/2026 1248567433
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,140.00 01/24/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362784
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 01/24/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362786
Principal investigator 1 Ocular Therapeutix, Inc. $55,468.00 01/22/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230901
Principal investigator 1 ANI Pharmaceuticals, Inc. $750.00 01/20/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
New Day Study No dispute reported 06/30/2026 1248567691
Principal investigator 1 Ocular Therapeutix, Inc. $7,273.00 01/17/2025 Non-covered Recipient Entity
California Retina Consultants
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration No dispute reported 06/30/2026 1250230891
Principal investigator 1 Genentech, Inc. $335.00 01/16/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211582689
Recipient Regeneron Pharmaceuticals, Inc. $2,055.00 01/14/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA No dispute reported 06/30/2026 1184117035
Principal investigator 1 Genentech, Inc. $908.00 01/13/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
Port Delivery System of Ranibizumab Extension Study No dispute reported 06/30/2026 1211582685
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184147107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184147109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,639.60 01/08/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184147111
Principal investigator 1 Apellis Pharmaceuticals, Inc. $150.00 01/03/2025 Non-covered Recipient Entity
California Retina Consultants
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250362762
Recipient Genentech, Inc. $1,570.00 01/02/2025 Covered Recipient Physician Not supplied No dispute reported 06/30/2026 1211535448
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.00 01/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184144570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 01/02/2025 Non-covered Recipient Entity
CALIFORNIA RETINA CONSULTANTS
A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) No dispute reported 06/30/2026 1184144572

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2019 Amount invested $0.00 1
PY2019 Value of interest $3,360.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

1 record · PY2019

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2019 US Retina LLC $0.00 $3,360.00 Shares Physician Covered Recipient No dispute reported 06/30/2026 655842915